BKHA SEC filings, in plain English
Everything Black Hawk Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 40 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: This S-4/A (Amendment No. 8) discloses that Black Hawk failed to timely make the November 2025 and December 2025 monthly extension payments of $150,000 each, and that the cure periods expired before the payments were made. The filing also reports that the Sponsor has issued a fifth convertible promissory note (August 2026, $300,000) and that Vesicor forgave $1,015,987.50 in advances under a Debt Forgiveness Agreement dated June 30, 2026. The proxy statement/prospectus sets a record date of September 1, 2026, and an extraordinary general meeting date of [ ], 2026, to vote on the business combination with Vesicor, which values Vesicor at $70 million. Why it matters: The late extension payments and the board's decision not to liquidate create legal risk that a court could determine Black Hawk should have dissolved, potentially jeopardizing the business combination. The additional convertible note and debt forgiveness increase sponsor dilution and alter the trust account dynamics for public shareholders.
What changed: Black Hawk Acquisition Corp filed an 8-K on August 26, 2026, reporting that on August 21, 2026, it issued a convertible promissory note to its Sponsor, Black Hawk Management LLC, with a principal amount of up to $300,000. The Note bears interest at 10% per annum starting July 8, 2026, for one year, and is unsecured. The Sponsor waived any claim against the trust account. Upon a DeSPAC Transaction or liquidation, the outstanding balance becomes due; in a DeSPAC Transaction, the Sponsor may elect cash repayment or conversion into common stock at $1.00 per share. In a liquidation, amounts are repaid in cash. Why it matters: This filing establishes a new financial obligation and potential dilution mechanism for investors. The waiver of claims against the trust account reduces the assets available for redemption if the SPAC liquidates, potentially impacting the value returned to shareholders who do not redeem. The conversion option provides the Sponsor with equity upside at a fixed price ($1.00), which could dilute existing public shareholders upon a business combination.
What changed: Black Hawk Acquisition Corp filed an 8-K on August 24, 2026, reporting that it deposited $150,000 into its trust account to extend the deadline for consummating its initial business combination by one month. The filing states this extension moves the deadline from August 22, 2026, to September 22, 2026. Why it matters: This confirms a redemption-relevant event: the SPAC has paid the required extension fee and successfully pushed back the date by which shareholders must decide whether to redeem their shares or remain invested in the pending deal. Investors tracking the timeline now have until September 22, 2026, for the next potential liquidity event or merger completion.
What changed: Amendment No. 7 to Registration Statement on Form S-4, containing a preliminary proxy statement/prospectus for an extraordinary general meeting to approve the business combination between Black Hawk Acquisition Corp. (SPAC) and Vesicor Therapeutics, Inc. This amendment updates the proxy statement/prospectus with: (1) disclosure that the November and December 2025 monthly extension payments were made after their 45-day cure periods expired, constituting a breach of the Current Charter and Trust Agreement; (2) the board's decision not to initiate liquidation despite the breach; (3) the June 30, 2026 Debt Forgiveness Agreement under which Vesicor forgave $1,015,988 in advances to Black Hawk; (4) updated trust account balance of $25,313,116 and redemption price estimate of $12.04 per share as of July 15, 2026; (5) revised pro forma financials reflecting the debt forgiveness and late payments; (6) updated risk factors regarding possible court-ordered liquidation; and (7) extension of the meeting date to [ ] 2026. Why it matters: The late extension payments and failure to liquidate create material legal and governance risk — a court could determine that Black Hawk was required to liquidate upon expiration of the cure periods, which could invalidate the business combination or lead to shareholder claims. The Debt Forgiveness Agreement reduces the target's receivable but also eliminates any conversion rights for those advances, altering the economics of the deal. The trust per share value ($12.04) exceeds the nominal $10.00, affecting redemption math. The PPM Investment condition remains unfilled and may be waived, risking Nasdaq listing. These developments directly bear on sponsor conduct, deal certainty, and post-close cash position.
What changed: Form 8-K Current Report filed under Item 8.01 (Other Events). According to the filing, an aggregate of $150,000 was deposited into Black Hawk Acquisition Corporation’s trust account for public shareholders. Chief Executive Officer Kent Louis Kaufman executed the report on July 22, 2026, confirming that this extension payment secures a one-month adjustment to the deadline for consummating the initial business combination, moving the cutoff from July 22, 2026, to August 22, 2026. No changes to equity structure, trading listings, or executive leadership were disclosed. Why it matters: For investors monitoring redemption calendars and trust mechanics, this extension delays any hard deadline that would force a public shareholder redemption vote or trigger automatic trust liquidation, keeping capital committed while management funds continued deal pursuit. The $150,000 deposit directly reduces the residual trust pool available to exiting shareholders, meaning each funded month marginally shrinks the per-share amount potentially distributable upon termination. The registrant reports its activity under Standard Industrial Classification code 2836 (Biological Products, No Diagnostic Substances) and Organization Name 03 Life Sciences, indicating the extension is intended to close targets or secure financing in that sector. Sponsor-funded extensions often reflect a conviction that a viable acquisition exists, but recurring payments can pressure trust value over time; investors should track subsequent disclosures for target specifics, financing milestones, or formal amendment filings detailing revised redemption or liquidation triggers.
What changed: Quarterly report on Form 10-Q for Black Hawk Acquisition Corp (BKHA), a SPAC that has announced a merger with Vesicor Therapeutics. The filing is the regular quarterly report for the period ended May 31, 2026. Key developments: (1) The merger with Vesicor (pre-money $70 million) remains pending; Amendment No. 3 to the S-4 was filed on March 4, 2026. (2) On March 31, 2026, Nasdaq notified the Company that its MVLS had fallen below $50 million for 30 consecutive business days; the Company has 180 days (to Sept 28, 2026) to regain compliance. (3) As of May 31, 2026, the trust holds $25,313,116 (at $11.92/share for 2,124,077 redeemable shares), up from $23,827,149 at Nov 30, 2025. (4) Vesicor forgave $1,015,988 of its advances (June 30, 2026), which will reduce the 'Due to target company' liability. (5) Working capital deficit was $2,688,676 and cash was $11,583; the Company reasserts a going concern doubt. (6) The convertible notes from the Sponsor ($1,232,366 outstanding) were modified to a fixed $1.00/share conversion price, qualifying for equity scope exception. (7) The Company is current on its $150,000/month extension payments through Dec 22, 2026. (8) Net income for the six months was $228,734 vs $1,178,921 in the prior-year period. Why it matters: The trust value is $11.92 per share, well above typical trust levels. The Company has cash liquidity concerns (only $11,583 outside trust) and faces a Nasdaq delisting notice. Vesicor's forgiveness of $1,015,988 will improve the balance sheet. The merger is still pending with no hard closing date.
What changed vs 2026-04-21trust $24.6M → $25.3M +3%trust account, combination deadline, going-concern doubt1 moved · 2 with no prior record of ours
- Trust account
- $24.6M$25.3M
- Combination deadline
- 2026-12-22 · unchanged
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as $672,525 was added to the trust between the two filings.
The clause “1 Prepaid expenses 51,547 11,269 Total Current Assets 63,130 50,790 Investments held in Trust Account 25,313,116 23,827,149 Total Assets $ 25,376,246 $ 23,877,939 Liabilities, Shares Subject to Redemption and Shareholders’ Deficit Current”…
The clause …“each for an additional one (1) month, from the current Termination Date to December 22, 2026, by depositing into the Trust Account $0.033 per remaining public share (after redemptions) for each monthly extension, in accordance with”…
The clause …“of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Amendment No. 6 to Registration Statement on Form S-4 (proxy statement/prospectus) for the business combination between Black Hawk Acquisition Corp (SPAC) and Vesicor Therapeutics, Inc., including proposals for domestication, merger, organizational documents, director election, Nasdaq issuance, incentive plan, NTA amendment, and adjournment. Updated disclosures include: (1) detailed description of late November and December 2025 extension payments, cure period expiration, and risk that a court could determine liquidation should have been initiated; (2) revised risk factors regarding potential delisting if PPM Investment ($10M) not obtained; (3) disclosure of Debt Forgiveness Agreement where Vesicor forgave $1,015,987.50 in advances; (4) updated pro forma financial statements under no, 50%, and maximum redemption scenarios; (5) updated share ownership tables with sliding scale Founder Share transfer mechanism (up to 865,000 shares); (6) inclusion of fairness opinion from EntrepreneurShares LLC; (7) trust balance of approximately $22.7 million after 69.2% public share redemption. Why it matters: This filing provides the definitive proxy statement for shareholder vote on the de-SPAC transaction. It reveals that the SPAC may have been required to liquidate due to late extension payments, creating legal uncertainty. The PPM Investment condition could be waived, risking Nasdaq listing. Sponsor convertible notes at $1.00/share will cause significant dilution. The Founder Share sliding scale mechanism could transfer up to 865,000 shares to target. Shareholders must consider these risks before voting.
What changed: Amendment No. 5 to Registration Statement on Form S-4 (S-4/A) — a proxy statement/prospectus filed by Black Hawk Acquisition Corp (BKHA) in connection with its proposed business combination with Vesicor Therapeutics, Inc. It is both a solicitation of proxies for an extraordinary general meeting and a prospectus for the securities to be issued by the post-combination company. This Amendment No. 5 updates the registration statement to include: (1) disclosure of late monthly extension payments (Nov 2025, Dec 2025) that were deposited after their respective cure periods expired, and the SPAC's decision not to liquidate despite acknowledging a breach of its governing documents; (2) a new May 2026 Convertible Note to the Sponsor for $300,000; (3) updated financial statements (Black Hawk unaudited for three months ended Feb 28, 2026; Vesicor unaudited for three months ended Mar 31, 2026); (4) updated pro forma financial information assuming multiple redemption scenarios; and (5) a sliding-scale mechanism for up to 865,000 Founder Shares that may be transferred to Vesicor shareholders post-closing depending on capital raised and post-de-SPAC stock price. Why it matters: The filing is highly material. It contains the first explicit disclosure that BKHA breached its charter and trust agreement by failing to make two monthly extension payments within the applicable cure periods and did not initiate liquidation as required. The SPAC acknowledges a court could conclude liquidation should have occurred, and that the SPAC and its directors could be subject to claims. This creates significant legal risk and uncertainty for the business combination. The filing also confirms the trust holds approximately $24.6M after the July 2025 redemptions of 69.2% of public shares. The SPAC must close a deal by Dec 22, 2026, per the extension plan, but its own past non-compliance undermines the structural integrity of that timeline. The sponsor's $1.3M in convertible notes at $1.00/share also create a massive dilutive incentive favoring closure over liquidation. The target, Vesicor, is a pre-revenue, pre-clinical biotech with no patents and a sole product candidate yet to commence IND-enabling studies, introducing high execution risk.
What changed: A Form 8-K current report announcing the execution of a convertible promissory note. Per Exhibit 10.1 attached to the filing, Black Hawk Acquisition Corp. entered into a financing arrangement with its sponsor, Black Hawk Management LLC, authorizing drawdowns of up to $300,000 for working capital and extension purposes. The note accrues interest at 10% per annum, commencing April 20, 2026, for a period of one year. Sponsor may request funds with issuance occurring within five business days. Upon completion of an initial business combination, the Sponsor holds the unilateral election to receive cash repayment or convert the outstanding principal into post-transaction ordinary shares at a fixed conversion price of $1.00 per share. In the event of liquidation, the note matures for cash payment, but the Sponsor expressly waived all claims and recourse against the company’s trust account. Why it matters: This unsecured credit facility supplies liquidity to fund potential trust extensions or operational runway without amending the statutory redemption deadline or encumbering public shareholder assets. The explicit trust account waiver shields investor proceeds from creditor claims if the SPAC dissolves, preserving redemption values intact. The $1.00 per share conversion mechanic caps sponsor dilution upside at deal close and activates automatic registration rights consistent with the March 20, 2024 registration agreement, clarifying post-transaction share class liquidity. No changes to the acquisition target, valuation parameters, or management roster are reported.
What changed: S-4/A (Amendment No. 4) — Preliminary proxy statement/prospectus for the extraordinary general meeting of Black Hawk Acquisition Corporation to approve the business combination with Vesicor Therapeutics, Inc., including the domestication from Cayman Islands to Delaware, merger, and related proposals. Amendment No. 4 updates the S-4 with: (1) disclosure that Black Hawk failed to timely deposit extension payments for November 2025 and December 2025, with the November payment made after the 45-day cure period expired, constituting a breach of the Current Charter and Trust Agreement; (2) the Board decided not to initiate liquidation despite the breach, creating potential litigation risk; (3) disclosure of a February 12, 2026 convertible note to the Sponsor for $300,000 at 10% interest, convertible at $1.00 per share; (4) receipt of Nasdaq MVLS deficiency notice on March 31, 2026, with a compliance period through September 28, 2026; (5) updated financial statements and pro forma information; (6) addition of employment agreements for PubCo executives; (7) revised risk factors including risks related to the extension payment breach and potential delisting. Why it matters: This filing is critical because it reveals that Black Hawk breached its governing documents by failing to make required extension payments within the cure period, and the Board chose not to liquidate. This creates legal exposure and could affect the validity of the business combination. The Nasdaq MVLS deficiency threatens continued listing. The $1.00 per share conversion price on sponsor notes (vs. ~$11.92 trust per share) will cause massive dilution to public shareholders. The PPM Investment condition ($10M) remains unmet and may be waived, potentially leading to delisting. These factors directly impact redemption decisions and the post-combination company's viability.
What changed: Amendment No. 1 to Black Hawk Acquisition Corporation's Form 10-K for the fiscal year ended November 30, 2025, originally filed March 6, 2026. It is filed solely to add the board-adopted Compensation Recovery (Clawback) Policy as Exhibit 97.1, which was inadvertently omitted; no other change is made and it does not update disclosure for later events. The cover page repeats that non-affiliate market value was approximately $73.9 million at May 31, 2025 and that 4,153,577 ordinary shares were outstanding at March 6, 2026. Why it matters: This is an exhibit-only correction with no economic content: no financial statement, trust figure, deadline or transaction disclosure changes, and the amendment expressly does not reflect events after the original March 6, 2026 filing. It matters only in the narrow sense that a missing clawback policy exhibit is a listing-rule compliance item that exchanges expect annual reports to carry, and the company has now cured it. Nothing here should change a view on Black Hawk's trust value or timeline.
What changed: Quarterly report (Form 10-Q) for Black Hawk Acquisition Corp (BKHA), a blank-check SPAC that has announced a merger with Vesicor Therapeutics. Trust value rose to $24.6M from $23.8M as of Nov 30, 2025. Extension deposits continued; convertible note balance increased to $997k from $595k. New $7k due to related party. Vesicor advanced $441k to the SPAC during the quarter. The Company deposited $600k into the Trust during the quarter. A Nasdaq deficiency notice was received on March 31, 2026 for MVLS falling below $50M. Why it matters: Trust per share is now $11.60, up from $11.22 at year-end, creating a small spread for remaining public holders. The sponsor and Vesicor are funding extensions via convertible notes and direct advances, but the SPAC still has a working capital deficit and a going concern warning. The Nasdaq deficiency adds a delisting risk if the merger is not completed or compliance regained before Sept 28, 2026. Vesicor's pre-money valuation is $70M, existing shareholders roll 100% equity, and Vesicor is funding half the extension payments and certain merger costs. The deal is now in Amendment No. 3 S-4 stage.
What changed vs 2025-10-21trust $71.8M → $24.6M -66%deadline 2027-03-22 → 2026-12-22trust account, combination deadline, going-concern doubt2 moved · 1 with no prior record of ours
- Trust account
- $71.8M$24.6M
- Combination deadline
- 2027-03-222026-12-22
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as $47,188,673 left the trust between the two filings.
The clause “1 Prepaid expenses 2,945 11,269 Total Current Assets 181,352 50,790 Investments held in Trust Account 24,640,591 23,827,149 Total Assets $ 24,821,943 $ 23,877,939 Liabilities, Shares Subject to Redemption and Shareholders’ Deficit Current”…
SpacBrain reads this as 90 days earlier than the previous record.
The clause …“each for an additional one (1) month, from the current Termination Date to December 22, 2026, by depositing into the Trust Account $0.033 per remaining public share (after redemptions) for each monthly extension, in accordance with”…
The clause …“of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 12b-25 Notification of Late Filing for a Quarterly Report on Form 10-Q. This notice documents that Black Hawk Acquisition Corporation missed the prescribed April 14, 2026 filing deadline for its quarterly report covering the period ended February 28, 2026. Regarding redemption deadlines, trust value mechanics, extension votes, deal progress, and sponsor conduct, the filing discloses no changes to any of these parameters. Why it matters: For an announced SPAC, missing a periodic filing deadline triggers exchange listing compliance reviews that can suspend trading, freeze shareholder redemption windows, or initiate delisting procedures before a merger vote or cash distribution occurs. The registrant attributed the delay to 'a delay experienced by the Registrant in completing its financial statement,' an accounting bottleneck that typically cascades into postponed auditor comfort letters, delayed trust reconciliations, and slower proxy finalization, thereby compressing the viable timeline for a business combination closing.
What changed: Form 8-K (Item 3.01) disclosing a Nasdaq Market Value of Listed Securities (MVLS) deficiency notice. The Nasdaq Listing Qualifications Department stated on March 31, 2026, that Black Hawk Acquisition Corporation’s MVLS fell below the $50,000,000 requirement for the trailing 30 consecutive business days. Acting through Chief Executive Officer Kent Louis Kaufman, the registrant reported it has a 180-calendar-day cure period ending September 28, 2026. To regain compliance, the company must maintain an MVLS of $50,000,000 or higher for a minimum of ten consecutive business days, though Nasdaq may exercise discretion to require up to twenty consecutive business days. Trading of units (BKHAU), rights (BKHAR), and class A ordinary shares (BKHA) will remain uninterrupted on the Nasdaq Global Market during the cure window. Why it matters: For investors monitoring SPAC execution mechanics, this filing introduces listing compliance risk without modifying the approved redemption timeline, trust distribution mechanics, extension schedule, or merger target trajectory. The filing explicitly notes that failure to meet the $50,000,000 benchmark by the September 28, 2026 deadline will trigger a written delisting notification. While the company outlines potential remediation routes—an appeal to a Nasdaq Listing Qualifications Panel or a request to transfer to the Nasdaq Capital Market—it attributes no guarantee to either outcome, stating there is 'no assurance' success. This listing vulnerability could compress secondary market liquidity and influence shareholder sentiment ahead of any combination vote, though the registrant confirmed no alterations to sponsor conduct, deal progress, or trust account terms.
What changed: A Form 8-K current report accompanying an executive employment agreement (Exhibit 10.1) and a corporate press release (Exhibit 99.1), filed pursuant to Items 5.02 and 7.01. Black Hawk Acquisition Corp reported that its proposed business combination target, Vesicor Therapeutics, Inc., appointed Dr. Michael Tolentino as Chief Executive Officer effective March 17, 2026, replacing founding CEO Luo Feng, who transitioned to Chief Scientific Officer. The attached employment contract establishes a three-year initial term, a $48,000 base salary (subject to upward revision if Vesicor raises a minimum of $5 million in equity capital), an ad hoc annual bonus at the Board's discretion, and a severance package equating to two times base salary plus target bonus, alongside 24 months of health insurance premium reimbursements, triggered by termination without cause or for Good Reason. The agreement enforces a non-competition clause for the employment duration plus one year, a 12-month non-solicitation covenant, and comprehensive intellectual property assignment under Florida law. In the accompanying press release, Vesicor reiterated its development roadmap, targeting an FDA IND submission in 2027 for its p53-based cancer therapeutics delivered via precision-engineered microvesicles, while confirming ongoing efforts to finalize the de-SPAC merger with Black Hawk. Why it matters: Changes in target-company executive leadership directly influence de-risking timelines prior to SPAC shareholder redemption decisions. Appointing an external biotech veteran signals a strategic pivot to accelerate clinical milestones, specifically the cited 2027 IND submission target. The notably modest $48,000 starting salary, explicitly conditional upon securing $5 million in equity, highlights immediate liquidity requirements that likely necessitate a PIPE financing round or post-merger capital raise, introducing potential dilution risks for redemption-track investors before proxy deadlines arrive. Additionally, the granular severance and restrictive covenants clarify the post-combination governance framework and management incentive alignment, providing transparency on how operational control will shift following the transaction.
What changed: Annual report on Form 10-K for fiscal year ended November 30, 2025, filed by Black Hawk Acquisition Corp, a blank-check SPAC seeking a business combination. The 10-K reports: (1) a definitive Business Combination Agreement with Vesicor Therapeutics, Inc. signed April 26, 2025, valuing Vesicor at $70 million pre-money; (2) shareholder approval on July 8, 2025 of an extension allowing up to 18 monthly extensions through December 22, 2026, each requiring a $150,000 deposit into the trust; (3) redemption of 4,775,923 public shares at ~$10.68 per share for ~$51.0 million, reducing the trust to ~$22.7 million; (4) trust per-share redemption value as of November 30, 2025 of $11.22 (compared to $10.41 a year earlier); (5) convertible notes issued to sponsor totaling $595,369 principal outstanding as of November 30, 2025; (6) a working capital deficit of $1.43 million and a going-concern warning; (7) a material weakness in internal control over financial reporting. Why it matters: Investors must track the reduced trust balance and per-share value for future redemptions, the extended deadline to December 2026, the sponsor's commitment to fund monthly extension payments (some paid late), and the pending deal with Vesicor. The trust per-share value of $11.22 is above the IPO price but may change with further redemptions or interest. The material weakness and going-concern note signal execution risk.
combination deadline, trust account, going-concern doubt +2nothing moved · 5 with no prior record of ours
- Combination deadline
- not previously extracted2026-12-22
- Trust account
- $71.8M · unchanged
- Going-concern doubt
- stated · unchanged
- Sponsor loans outstanding
- $250Knot matched in this filing
- Mandate language
- we intend to focus our search for an initial business combin… · unchanged
The clause …“deferred underwriting commissions). If we are unable to consummate an initial business combination by December 22, 2026, or such earlier date as may apply if the extension is not continued, we will redeem the remaining outstanding”…
The clause …“(Level 2) Significant Other Unobservable Inputs (Level 3) Assets Investments held in Trust Account $ 71,829,264 $ 71,829,264 - - F- 21 Note 10 — Segment Information ASC Topic 280, “Segment Reporting,” establishes standards for”…
The clause …“of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Amendment No. 3 to Registration Statement on Form S-4 (proxy statement/prospectus) filed by Black Hawk Acquisition Corp (SPAC) and co-registrant Vesicor Therapeutics, Inc. in connection with the proposed business combination. This filing updates and amends the S-4 registration statement with (i) disclosure that the November 2025 and December 2025 monthly Extension Payments of $150,000 each were made after their 45-day cure periods expired, constituting a breach of the governing documents and trust agreement; (ii) the January 2026 payment was made within the cure period; (iii) the Board decided not to commence liquidation despite the breach, citing full eventual deposits and pursuit of the business combination; (iv) a third unsecured convertible note of $300,000 was issued to the Sponsor on February 12, 2026 at 10% interest, convertible at $1.00 per share; (v) the June 2025 convertible note was amended on September 30, 2025 to fix the conversion price at $1.00; (vi) updated redemption data: 69.2% of public shares redeemed in July 2025, leaving 2,124,077 public shares and ~$22.7 million in trust; (vii) sliding-scale founder share transfer of up to 865,000 shares to Vesicor based on post-closing share price; and (viii) PPM Investment of at least $10 million required as condition to closing, but waivable. Why it matters: The late extension payments and the Board's failure to liquidate create material legal risk—a court could conclude the SPAC should have liquidated, potentially invalidating the business combination or exposing directors to claims. The new convertible notes at $1.00/share conversion price will massively dilute public shareholders if converted (up to 1,000,000 shares). The PPM Investment condition is critical because if waived, Nasdaq listing standards for shareholders' equity may not be met, risking delisting. The sliding-scale founder share transfer changes post-closing ownership. The high redemption rate (69%) reduces trust cash and increases reliance on the uncertain PPM. Investors need to assess these risks before the shareholder vote.
What changed: SEC Form 12b-25, Notification of Late Filing (routine compliance exhibit) declaring that Black Hawk Acquisition Corporation could not submit its Annual Report on Form 10-K by the March 2, 2026 deadline applicable to smaller reporting companies. The registrant’s filing schedule has been extended internally. Why it matters: For SPACs, delayed 10-K submissions directly compress the timeline to satisfy merger closing conditions, typically require audited financials, and can trigger automatic liquidation or mandatory extension votes if the corporate charter ties the deSPAC window to fiscal-year reporting deadlines. The postponement raises sponsor conduct and execution risk: Mr.
What changed: A Form 8-K current report disclosing Entry Into a Material Definitive Agreement and Creation of a Direct Financial Obligation, specifically detailing a Convertible Promissory Note issued by Black Hawk Acquisition Corp. to its sponsor, Black Hawk Management LLC, with the full contractual exhibit attached. The issuer authorized a borrowing facility capped at $300,000 accruing interest at 10% per annum, deployable for working capital or extension purposes upon five-day funding timelines. Regarding trust and redemption mechanics, Section 12 of the Note contains an explicit Trust Waiver wherein the Sponsor formally relinquishes all rights, title, interests, or claims against the trust account established from IPO proceeds, legally insulating the reported $11.92 per share trust value from this debt obligation. Upon a DeSPAC Transaction closing, the Sponsor retains election rights to accept cash repayment or convert the outstanding principal into ordinary shares at a fixed $1.00 per share price, with share counts rounded up to the nearest whole share. Should liquidation occur prior to a business combination, the covenant mandates full cash settlement. Conversion proceeds grant registration rights consistent with the agreement dated March 20, 2024. Why it matters: As structured by the sponsor and issuer, this financing architecture prevents trust account erosion during the announced deal’s execution phase, thereby preserving public shareholder redemption liquidity. The explicit carve-out for 'extension purposes' indicates tactical runway supplementation to support the timeline for the previously announced business combination without triggering early termination or margin calls. At maximum drawdown and full conversion, the instrument introduces a defined dilution vector of up to 300,000 shares, subject to standard registration protocols that do not impede post-merger trading. According to the filing signatures, Chief Executive Officer Kent Louis Kaufman authenticated the 8-K disclosure and COO Jonathan Ginsberg executed the Note. The document contains no forward-looking projections, customer acknowledgments, revenue commitments, market size estimates, technology roadmaps, commercial partnership validations, litigation exposures, or executive departures; it exclusively governs sponsor lending covenants and corporate finance contingencies.
What changed: SEC Form 8-K current report filed under Item 5.02, classified in its own terms as a disclosure of departures, elections, and appointments of directors and certain officers, alongside associated compensatory arrangements. The filing reports that Michael Bowen, the Chief Financial Officer of Vesicor Therapeutics, Inc. (the proposed business combination target), passed away on January 27, 2026. Following that event, the Vesicor Board appointed Mitchell Creem as Chief Financial Officer effective immediately, noting there is no employment agreement between Vesicor and Mr. Creem. Additionally, the Vesicor Board appointed Frederick Woodruff Field as a board member effective January 26, 2026, and determined that he satisfies Nasdaq independence rules. The report contains no adjustments to redemption deadlines, trust account balances, extension provisions, or sponsor conduct. Why it matters: The loss of a target company’s CFO mid-combination signals operational transition risk that may influence deal execution timelines and shareholder approval dynamics. Vesicor explicitly states that it believes Mr. Creem’s background, including more than 35 years in senior healthcare executive roles and prior tenure as CFO of ApolloMed, makes him well qualified to serve. Vesicor also asserts that it believes Mr. Field’s background, encompassing over 30 years in media and investments alongside founding Interscope Communications in 1982 and Radar Pictures in 2001, makes him well qualified for the board seat. The filing confirms neither appointee holds a family relationship with the SPAC’s directors or executives, has material interests under Regulation S-K Item 404(a), and was selected pursuant to separate arrangements. Because the new CFO operates without a signed employment contract, investors tracking post-merger integration readiness and management retention covenants should monitor for subsequent filings that may address deferred compensation, voting thresholds, or timeline amendments. The absence of mechanical updates leaves the existing redemption calendar and trust structure unaffected, but the personnel shift warrants close tracking for potential impacts on due diligence completion and SPAC sponsor alignment.
What changed: Amendment No. 2 to a Form S-4 registration statement, comprising a preliminary proxy statement/prospectus for Black Hawk Acquisition Corporation's extraordinary general meeting of shareholders, at which they will vote on the proposed business combination with Vesicor Therapeutics, Inc. and related proposals. This is a routine S-4/A amendment that updates the registration statement but does not introduce new core deal terms. The document restates the existing deal structure: Black Hawk (SPAC) will merge with Vesicor (a pre-revenue biotech), the combined company will be renamed Vesicor Therapeutics Holdings, Inc. and list under 'VESI'. It details the specific terms of the financing, including a required $10 million PPM Investment, the extension mechanics, and sponsor compensation. The most recent status disclosed is that only 2,124,077 public shares remain outstanding, with approximately $22.7 million in the trust account. The deal timeline is now expected to close in Q1 2026. Why it matters: The filing is critical for investors tracking the deal's financing status and the potential for significant dilution. The closing is contingent on Vesicor procuring a $10 million PPM Investment, but no commitments have been received, and both Vesicor and Black Hawk may waive this condition. If waived, the combined company may not meet Nasdaq's $5 million shareholders' equity requirement and could be delisted. Additionally, the sponsor's $700,000 in convertible notes can be converted into 700,000 shares at a $1.00 per share conversion price, creating notable dilution for public shareholders. The filing also confirms Sponsor and Vesicor have each funded $750,000 in extension payments, and outlines the potential transfer of up to 865,000 Founder Shares to Vesicor shareholders based on a sliding scale.
What changed: Amendment No. 1 to Registration Statement on Form S-4 (S-4/A) filed jointly by Black Hawk Acquisition Corp (SPAC) and Vesicor Therapeutics, Inc. (co-registrant) as a preliminary proxy statement/prospectus in connection with a business combination agreement. This filing is an amended registration statement containing an updated, more comprehensive version of the proxy statement/prospectus last filed. Key numerical updates and new disclosures include: (1) Trust account now holds approximately $22.7 million after 69.2% of public shares ($51.0M) were redeemed at ~$10.68 per share in July 2025, leaving 2,124,077 public shares outstanding; (2) total trust per share as of August 31, 2025 was $10.97; (3) the SPAC has funded $750,000 in extension payments (five $150k monthly deposits); (4) the Sponsor now holds two convertible notes ($350k at 6%, $350k at 10%, both convertible at $1.00), meaning $700,000 could convert into up to 700,000 shares; (5) the PPM Investment condition requires Vesicor to obtain at least $10 million pre-close, with disclosure that neither party has commitments yet; (6) pro forma net tangible book value per share at max redemptions is negative ($1.38); (7) in the maximum redemption case, a sliding scale transfers up to 865,000 founder shares to Vesicor holders subject to a post-closing 20-day VWAP trigger; (8) detailed conflicts of interest disclosures reveal $500k in cash performance incentives ($200k to CEO Feng, $300k to COO Hosseinion Jr.) to be ratified by PubCo's board at close. Why it matters: This filing contains critical mechanics for redemption calendar, trust value, and deal completion. Only ~$2.6M in non-trust cash existed as of Aug. 31, 2025 ($15k cash, working capital deficit of ~$902k). The massive July 2025 redemptions (69.2% of shares) left only $22.7M in trust. The combination of $700k in sponsor notes convertible at $1.00/share (a ~90% discount to the $10.97 trust value per share) creates severe potential dilution: up to 700,000 shares could be issued to the sponsor at well below trust value. The deal is at risk of failure to meet Nasdaq listing standards if the $10M PPM Investment is not completed; the document explicitly warns that waiver of the PPM condition would cause the combined company to not satisfy the $5M shareholders' equity requirement, risking delisting to the OTC market. The $70M valuation is based on equity value / redemption price, so the higher the redemptions, the fewer shares Vesicor holders get relative to the fixed $70M numerator, altering ownership splits significantly. The filing is also material for its extensive disclosure of Sponsor conflicts: founder shares acquired for $25k now worth ~$9.4M at $10.97 trust value; extension payments represent capital at risk that incentivizes closing any deal.
What changed: A delaying amendment (filed pursuant to Rule 473 under the Securities Act of 1933) to Registration Statement on Form S-4 (File No. 333-292402) for Black Hawk Acquisition Corporation. Chief Executive Officer and Chairman Kent Kaufman executed a delaying amendment on the 29th day of December 2025 to suspend the effective date of the S-4 statement initially filed on December 23, 2025. Why it matters: This administrative toll halts the statutory clock for S-4 effectiveness, thereby deferring any downstream shareholder meeting, proxy solicitation, or redemption deadline contingent on an active registration statement. The filing introduces no new valuation metrics, cash extension provisions, or revised deal structures. Because the registrant relies on the standard Rule 473 waiver rather than amending specific term sheets or shareholder approval thresholds, existing sponsor commitments and the target transaction’s status remain unaltered.
What changed: An S-4 Registration Statement filed by Black Hawk Acquisition Corp. (BKHA) with the SEC on December 22, 2025, which serves as a combined proxy statement/prospectus for an extraordinary general meeting where shareholders will vote on a proposed business combination (de-SPAC) with Vesicor Therapeutics, Inc. This is the initial S-4 filing for the de-SPAC. The document reveals that after the July 2025 extension vote, 69.2% of public shares were redeemed (~$51M), leaving ~2.1M public shares outstanding and ~$22.7M in the trust (trust/value ~$11.92). The sponsor has funded $750k in extension payments via convertible notes at $1.00/share. The deal values Vesicor at a $70M equity value. The combined company is required to secure a $10M PPM Investment as a condition to close; if waived, it will fail Nasdaq's $5M equity listing requirement and may be delisted. The target is a pre-revenue biotech with one product candidate, no patents filed, and no FDA approvals. Why it matters: This filing is the primary disclosure document for the de-SPAC vote. The material risk is the PPM condition: the target itself is uncertain it will close the $10M PIPE. If the condition is waived and shares are delisted, public shareholders may face an over-the-counter market and a potential near-total loss of liquidity. The near-70% redemption rate and the sponsor's ability to convert notes at a 90% discount ($1 vs $10 IPO) are significant sponsor conduct signals. The target is at the preclinical stage and its key technology claims are based on unverified case studies from Japan that Vesicor explicitly states cannot be relied upon.
What changed: A Routine Compliance Exhibit: Joint Filing Statement (Exhibit I) appended to a Schedule 13G/A amendment, filed by First Trust Merger Arbitrage Fund, First Trust Capital Management L.P., First Trust Capital Solutions L.P., and FTCS Sub GP LLC to designate co-filers for their beneficial ownership report on Black Hawk Acquisition Corp. The exhibit records no change to beneficial ownership percentages, acquisition dates, or transaction purposes because the underlying Schedule 13G/A text is not included; it merely formalizes a joint filing arrangement under SEC Rule 13d-1(k). Nothing in the filing alters or references redemption deadlines, trust value adjustments, extension motions, deal progress, or sponsor conduct. The document confirms the named First Trust entities continue to hold positions in BKHA but introduces no new contractual terms, cash retention metrics, or voting schedules that would impact shareholder redemptions or merger timing. Why it matters: Beyond confirming institutional holding continuity, the filing contains no substantive operational, financial, or strategic claims attributable to Black Hawk Acquisition Corp. management, advisors, or third parties. The only personnel referenced are administrative signatories Joy Ausili (Trustee, Vice President, and Assistant Secretary) and Chad Eisenberg (Chief Operating Officer), who individually acknowledge responsibility for the joint statement’s completeness and accuracy. With zero economic figures, market projections, partnership announcements, or litigation details present in the text, this submission carries no immediate bearing on trust recovery, deal progression, or investor exit windows. Market participants should await subsequent proxy statements, business combination agreements, or press releases for actionable developments.
What changed: A Joint Filing Statement pursuant to Rule 13D-1(k)(1), submitted as an exhibit to a Schedule 13G/A. Kerry Propper and Antonio Ruiz-Gimenez individually executed the statement consenting to jointly file a Schedule 13G for Black Hawk Acquisition Corporation shares under Rule 13d-1(k)(1)(iii), and stipulated that the agreement may be terminated upon written notice or a mutually agreed lesser period. Bearing on the requested mechanical tracking parameters, the signatories made no representations regarding redemption deadlines, trust value, extension procedures, deal progress, or sponsor conduct. Bearing on all other substance, they advanced no claims concerning customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, and introduced no numerical figures. Why it matters: This is a routine compliance exhibit governing SEC beneficial-ownership reporting procedure. It does not alter BKHA’s trust account administration, does not modify redemption or extension timelines, does not signal new merger milestones, and leaves sponsor conduct or obligations unchanged. It merely confirms alignment between two named parties for the purposes of regulatory disclosure for the same equity class.
What changed: Schedule 13G/A amended beneficial ownership report (routine compliance exhibit). The filing amends prior Section 13(d) disclosures by AQR Capital Management, LLC; AQR Capital Management Holdings, LLC; and AQR Arbitrage, LLC. Concerning SPAC mechanics, the provided excerpt contains no updated share counts, transaction dates, or threshold revisions. It does not modify redemption deadlines, adjust trust value parameters, trigger extension provisions, advance or delay deal progress, or reflect sponsor conduct. Why it matters: Institutional 13G/A filings of this type generally record passive position aggregation, custodial transfers, or internal reorganizations rather than active arbitrage positioning. The excerpt lacks percentage disclosures, acquisition dates, or purpose statements needed to gauge redemption pressure, underwriter commitment status, or voting alignment. It contains no substantive claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel.
What changed: SEC Schedule 13G/A — Amendment to a Beneficial Ownership Report. The amended filing updates a prior 13G submission on behalf of W. R. Berkley Corporation and Berkley Insurance Company. The provided excerpt does not disclose share quantities, percentage ownership levels, transaction dates, or the specific nature of the amendment. Consequently, the filing documents no change in redemption block composition, trust distribution mechanics, announced deal timeline, or sponsor conduct. Why it matters: Schedule 13G/A disclosures monitor shifts in institutional equity concentration that can eventually influence redemption behavior or future proxy voting dynamics. Because this excerpt lacks actual ownership metrics, it carries no direct bearing on the stated $11.92 per-share trust value, the DEAL_ANNOUNCED status, or extension deadlines. If the complete exhibit reveals a substantial increase in holdings or a crossover past statutory reporting thresholds, it may signal accumulating institutional liquidity or strategic positioning ahead of the business combination vote; absent those figures, the report remains a routine compliance update.
What changed: Quarterly report on Form 10-Q for the quarter ended August 31, 2025, filed by Black Hawk Acquisition Corporation (BKHA), a blank-check company. The Company entered into a definitive Business Combination Agreement with Vesicor Therapeutics, Inc. on April 26, 2025, valuing Vesicor at a pre-money equity value of $70 million. On July 8, 2025, shareholders approved an extension of the business combination deadline from June 22, 2025 to December 22, 2026, with monthly deposits of $150,000 into the trust account. In connection with the extension vote, holders of 4,775,923 public shares redeemed, reducing the trust account from $71,829,264 to $23,296,572 and public shares outstanding from 6,900,000 to 2,124,077. The Company issued a convertible note to the sponsor for up to $350,000 on June 13, 2025, and another for up to $350,000 on September 23, 2025, to fund working capital and extension payments. The board of directors experienced a change: Brandon Miller died on April 29, 2025, and Daniel M. McCabe and Terry W. Protto assumed new committee roles. The Company reported a working capital deficit of $901,638 and management has raised substantial doubt about the Company's ability to continue as a going concern. Why it matters: This filing is material because it provides the first detailed financial update since the announcement of the definitive business combination with Vesicor, a biotech company developing p53-based cancer therapeutics. The trust account per-share value has dropped from $10.41 to $10.97 (adjusted for redemptions), but the trust has been cut by two-thirds. The extension terms ($150,000/month) and sponsor convertible notes reveal the company's reliance on sponsor support to survive. The going concern disclosure and working capital deficit indicate significant risk. The filing also discloses the death of a board member, which may affect governance. All these factors directly impact redemption deadlines, trust value, and deal completion probability.
What changed vs 2025-06-26trust $73.4M → $71.8M -2%deadline 2026-12-22 → 2027-03-22trust account, combination deadline, going-concern doubt2 moved · 1 with no prior record of ours
- Trust account
- $73.4M$71.8M
- Combination deadline
- 2026-12-222027-03-22
- Going-concern doubt
- stated · unchanged
SpacBrain reads this as $1,533,534 left the trust between the two filings.
The clause …“(Level 2) Significant Other Unobservable Inputs (Level 3) Assets Investments held in Trust Account $ 71,829,264 $ 71,829,264 - - August 31, 2025 Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2)”…
SpacBrain reads this as 90 days later than the previous record.
The clause …“(21) one-month extensions, from June 22, 2025 (the “Termination Date”) to March 22, 2027, for a maximum of 36 months from the date of the IPO; (ii) A related proposal by special resolution to amend the Trust Agreement, dated March”…
The clause …“of a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: A Form 12b-25, Routine Compliance Exhibit titled Notification of Late Filing, submitted by Black Hawk Acquisition Corporation to declare that its quarterly report on Form 10-Q for the period ended August 31, 2025, cannot be filed by the prescribed SEC deadline. No mechanics governing redemptions, trust distributions, business combination extensions, or sponsor equity forfeitures have shifted. The registrant stated the delay occurred because the company was unable to compile the necessary financial information required to prepare a complete filing. Why it matters: While the notification carries no direct weight on deal valuation or shareholder payout formulas, it signals an accounting or audit preparation bottleneck at the sponsor level that investors in a PIPE-adjacent or arbitrage position typically price into liquidity spreads. Under Rule 12b-25, the company must file on or before the fifth calendar day following the original due date; missing that window invites exchange listing deficiency notices, which historically constrain secondary trading volume and can complicate final shareholder vote timing relative to hard redemption deadlines.
What changed: Schedule 13G beneficial ownership report. The filing identifies Wolverine Asset Management LLC, Wolverine Trading Partners, Inc., Wolverine Holdings, L.P., Christopher L. Gust, and Robert R. Bellick as related parties jointly submitting a Schedule 13G to report aggregate beneficial ownership in BKHA. The provided excerpt contains no share quantities, percentage thresholds, acquisition dates, purchase prices, or stated investment purposes. Why it matters: This document does not disclose or alter redemption deadlines, trust value mechanics, extension motions, deal progression milestones, or sponsor conduct. It also contains no substantive operational claims regarding customer concentration, revenue figures, addressable market sizing, strategic initiatives, proprietary technology, commercial partnerships, active or threatened litigation, or executive personnel adjustments. As a standard aggregate ownership disclosure lacking quantified stakes or voting intent, it does not recalibrate estimated redemption pressure, modify deal timing assumptions, or signal activist accumulation that would impact shareholder decision-making.
What changed: A Form 8-K current report filed under Item 8.01 disclosing a trust account funding event to delay a corporate deadline. Black Hawk Acquisition Corp filed that an aggregate $150,000 extension payment was deposited into its trust account for public shareholders. According to the filing, this capital injection extends the period to consummate an initial business combination by one month, shifting the expiration from September 22, 2025, to October 22, 2025. Why it matters: Public shareholders now face a revised liquidation horizon of October 22, 2025, which dictates the final window to exercise redemption rights before a potential dissolution vote. The $150,000 deposit directly increases the aggregate trust balance held for public holders, though per-share trust math is not restated. The exhibit discloses no updates on target pipeline negotiations, operational metrics, technology roadmap, partnerships, or litigation, and carries no written communications or soliciting material flags. Chief Executive Officer Kent Louis Kaufman signed the report on behalf of the registrant.
What changed: A preliminary proxy statement/prospectus and Amendment No. 1 to a Form S-4 registration statement filed in connection with a proposed reverse triangular merger and business combination between Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. Why it matters: The disclosure materially alters redemption timing and post-deal survival odds: the explicit waiver pathway for the $10,000,000 PPM investment creates direct Nasdaq delisting exposure if trust proceeds are exhausted, while the strict two-business-day certificate delivery deadline removes the traditional SPAC 'option window' for retail exit.
What changed: Form 8-K Current Report filed under Item 8.01 Other Events disclosing a trust account deposit and corresponding business combination deadline extension. Black Hawk Acquisition Corp, attested by Chief Executive Officer Kent Louis Kaufman, deposited an aggregate of $150,000 (the “Extension Payment”) into the corporate trust account for public shareholders. The funding formally extends the period to consummate an initial business combination from August 22, 2025 to September 22, 2025. Why it matters: The filing mechanically pushes the SPAC redemption and merger deadline forward by exactly one calendar month to September 22, 2025, financed through a discrete $150,000 contribution. Beyond confirming the extension trigger and trustee funding event, the document contains no disclosures regarding a target entity, proposed transaction size, pipeline progression, customer contracts, operational metrics, technology, strategic partnerships, litigation, or executive transitions outside the routine signature block.
What changed: This filing consists of Exhibit A and Exhibit B to a Schedule 13G/A, formally structured as a Limited Power of Attorney executed by Mizuho Financial Group, Inc., Mizuho Bank, Ltd., Mizuho Americas LLC, and Mizuho Securities USA LLC. According to signatures by Hidekatsu Take and Adam Hopkins, the instrument grants Takahiro Katsura execution authority to prepare and file regulatory forms on behalf of those entities. The document contains no provisions, disclosures, or conditional language that alter Black Hawk Acquisition Corp.’s redemption window, specify trust account distribution amounts per share, define extension vote thresholds, report merger due diligence or closing milestones, or impose new governance rules or lock-up restrictions on the sponsor. Why it matters: Because the text operates solely as a routine compliance authorization listing executive titles and corporate office addresses in Tokyo and New York, it yields no substantive data on target revenue streams, customer concentrations, addressable markets, strategic initiatives, technology development, partnership structures, active litigation, or senior leadership movements beyond the named signatories. The filing represents standard administrative housekeeping for beneficial ownership reporting under Section 13(d) and Section 13(g) of the Exchange Act and carries no direct bearing on shareholder liquidity mechanics, deal financing conditions, or sponsor accountability metrics. false, 0.95
What changed: A Form 8-K Current Report (Item 8.01 Other Events) filed by Black Hawk Acquisition Corporation disclosing a trust account funding transaction and a corresponding extension of the initial business combination deadline. Per the registrant’s disclosure, an aggregate of $150,000 (the “Extension Payment”) was deposited into the trust account for public shareholders. The filing states this payment extends the period to consummate the initial business combination by one month, shifting the deadline from July 22, 2025 to August 22 2025. Why it matters: The extension materially resets the redemption window and trust timeline. Public shareholders retain their cash-out rights through August 22 2025, delaying any mandatory trust distribution or liquidation event. The $150,000 deposit signals active sponsor funding of monthly extensions, which typically comes from related parties or insiders and is credited to preserve per-share trust balances for redeeming holders. Chief Executive Officer Kent Louis Kaufman executed the report on August 7, 2025. Aside from the extension mechanics, the filing restates standard corporate identifiers: the company is incorporated in the Cayman Islands, operates from Suite 166 at 4125 Blackhawk Plaza Circle in Danville, California, retains an Emerging Growth Company election without opting out of extended transition periods, and lists Units (BKHAU), Ordinary Shares (BKHA), and Rights (BKHAR) on The Nasdaq Stock Market LLC under SIC 2836. No target identification, revenue metrics, strategic partnerships, litigation, or personnel changes are reported in this submission.
What changed: Schedule 13G, a routine compliance exhibit and beneficial ownership report filed on 2025-08-08 by W. R. Berkley Corporation and Berkley Insurance Company. The filing excerpt names the corporate filers and states the document type, but contains no share counts, acquisition dates, purchase prices, or percentage of outstanding securities. As a result, it provides no update on redemption deadlines, trust value mechanics, extension triggers, merger development milestones, or sponsor conduct. Why it matters: The submission confirms that a corporate insurer has registered a passive equity position in Black Hawk Acquisition Corp., but the provided text contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. All observations regarding the absence of financial metrics, deal timeline updates, and mechanical indicators are attributed directly to the limited scope of the submitted filing excerpt, which discloses no numerical figures whatsoever.
What changed: Schedule 13G/A — a beneficial ownership report filed by KARPUS MANAGEMENT, INC. The supplied excerpt identifies only the filing category, SEC accession number [0001072613-25-000507], and the reporting entity. It does not disclose updated share counts, ownership percentages, acquisition dates, or transaction purposes within the text provided. Why it matters: This document is a routine regulatory compliance exhibit tracking institutional or strategic equity positions rather than SPAC structural developments. It discloses zero information regarding redemption deadlines, trust value per share, extension timelines or procedures, target business negotiations, or sponsor conduct. Any assertions regarding portfolio activity or investment rationale are attributed exclusively to KARPUS MANAGEMENT, INC. as the named filer. Without the full exhibit schedule, the amendment carries no immediate weight for deal mechanics or trust administration.
What changed: A confidentially submitted draft amendment to a registration statement on Form S-4 functioning as a preliminary proxy statement/prospectus soliciting shareholder votes for a statutory domestication, reverse triangular merger, and business combination between Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. Why it matters: Per the proxy statement, the extended deadline and funded extension payments align sponsor economic survival with deal completion while isolating liquidity execution risk on Vesicor to independently raise $10,000,000.00 concurrently with closing. The agreement structures founder share transfers from the Sponsor to Vesicor stockholders on a sliding scale tied to unmet capital thresholds, directly linking insider wealth preservation to PIPE success.
What changed: Amended Current Report on Form 8-K (8-K/A) under Item 8.01 'Other Events', filed by Black Hawk Acquisition Corp to clarify and replace prior disclosures regarding the results of its extraordinary general meeting of shareholders. According to the registrant’s disclosure signed by Chief Executive Officer Kent Louis Kaufman, holders of 4,775,923 ordinary shares exercised their right to redeem those shares following the shareholder vote on July 8, 2025. The filing states that approximately $51,010,745.30 (approximately $10.68 per share) will be removed from the Trust Account to pay those holders. As a result, approximately $22,686,871.39 will remain in the Trust Account. The Company specifies that following the redemption, it will have 2,124,077 public ordinary shares issued and outstanding, with a total of 4,153,577 ordinary shares issued and outstanding. The amendment explicitly replaces the original Item 8.01 from the July 14, 2025 filing and notes that no subsequent events occurred after the original filing date. Why it matters: This amendment finalizes the trust payout calculation at $10.68 per redeemed share and locks the remaining trust balance at $22,686,871.39, directly recalibrating the per-share trust value for surviving public holders and defining the exact capital pool available for deal execution. The confirmed reduction of public float to 2,124,077 shares adjusts the public-to-sponsor ownership ratio and voting power ahead of the merger close. Beyond redemption mechanics, the filing discloses that the Cayman Islands exempted company operates under Standard Industrial Classification code 2836 for Biological Products (No Diagnostic Substances) and identifies the target organization name as 03 Life Sciences. Principal operations are directed from Suite 166, 4125 Blackhawk Plaza Circle, Danville, CA 94506.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.